Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094 | 0.87 | — | — | |
| SCHEMBL30234788 | 0.87 | DGAT1 (0.42) | DGAT1MAOAMAOBLMNAHSD17B10 | |
| SCHEMBL28902273 | 0.87 | DGAT1 (0.42) | DGAT1MAOAMAOBLMNAHSD17B10 | |
| SCHEMBL28325001 | 0.87 | DGAT1 (0.42) | DGAT1MAOAMAOBLMNAHSD17B10 | |
| Acetonitrile SCHEMBL20679756 | 0.85 | CTSK (0.36) | DGAT1MAOAMAOBLMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL8549932 | 0.84 | DGAT1 (0.40) | DGAT1MAOAMAOBLMNAHSD17B10 | |
| SCHEMBL28616368 | 0.84 | — | — | |
| SCHEMBL30702219 | 0.84 | — | — | |
| Methylamine SCHEMBL25305181 | 0.84 | DGAT1 (0.40) | DGAT1MAOAMAOBLMNAHSD17B10 | |
| Potassium SCHEMBL29411221 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. | 2024-12-03 | — | — | US | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-113372345-B | Deuterated heterocyclic kinase inhibitors | 山东轩竹医药科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-07-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| CN-112574211-B | Heterocyclic kinase inhibitors | 山东轩竹医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-112574179-B | DNA-PK inhibitors | 山东轩竹医药科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-110511220-B | P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine | 上海挚盟医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-113372345-A | Deuterated heterocyclic kinase inhibitors | 山东轩竹医药科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2021-06-03 | — | — | US | disclosed |
| CN-101437829-A | Bisadenosine compounds as adenosine A2A receptor agonists | NOVARTIS AG (CH) | 2009-05-20 | — | — | CN | disclosed |
| CN-101296906-A | (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| CN-101277700-A | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-01 | — | — | CN | disclosed |
| CN-101180297-A | Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors | CONFORMA THERAPEUTICS CORP (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-101048418-A | PI 3-kinase | BOEHRINGER INGELHEIM INT (DE) | 2007-10-03 | — | — | CN | disclosed |
| CN-101023064-A | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMA (US) | 2007-08-22 | — | — | CN | disclosed |
| CN-101014603-A | Compounds and methods for inhibiting mitosis by inhibiting aurora kinase | MILLENNIUM PHARM INC (US) | 2007-08-08 | — | — | CN | disclosed |
| CN-1777427-A | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN INC (US) | 2006-05-24 | — | — | CN | disclosed |
| CN-1726218-A | Pyrrolopyrimidine derivatives | PFIZER PROD INC (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1241176-A | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER (US) | 2000-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | DGAT1 2754/4885MAOA 1302/4885MAOB 1320/4885 |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | DGAT1 2754/4885MAOA 1302/4885MAOB 1320/4885 |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | DGAT1 2737/4885MAOA 1299/4885MAOB 1329/4885 |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | DGAT1 2737/4885MAOA 1299/4885MAOB 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.